Advaxis to Present at the 2011 10th Annual BIO Investor Forum on October 25th

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced that Tom Moore, Chairman and Chief Executive Officer, will present at the 10th Annual BIO Investor Forum on Tuesday, October 25th in San Francisco.

Advaxis’ presentation will begin at 9:30 a.m. PST. A live webcast of the presentation will be available on the Company's website at www.advaxis.com.

About the 10th Annual BIO Investor Forum

The 10th Annual BIO Investor Forum assembles a select group of public and venture-stage growth companies, as well as top public and private equity investors, to explore investment trends and opportunities in life sciences. In addition to expert-led workshops and panel discussions focusing on industry trends, the conference features presentations by over 100 biotech companies poised to join the growth “watch list” in 2011, as well as a number of nonprofit and venture philanthropy organizations. For more information, please visit the BIO Investor Forum website.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer, itself.

ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
[email protected]

KEYWORDS:   United States  North America  California  New Jersey

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Infectious Diseases  Oncology  Consumer  General Health  Men

MEDIA:

Logo
 Logo

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.